Akkermansia muciniphila in metabolic disorders: PRISMA-screened narrative review
A review of 43 reports suggests A. muciniphila supplementation improves insulin resistance, body weight, fat mass, and cholesterol, but heterogeneity and risk of bias prevent firm conclusions.
| Population | — |
|---|---|
| Intervention | — |
| Comparator | — |
| Outcome | — |
What the study showed
The narrative synthesis identifies evidence for improvements in insulin resistance, reductions in weight, fat mass, and cholesterol, with potential effects on prediabetes, lipid profiles, liver enzyme activity, gut microbiome diversity, and GLP-1 stimulation. Pasteurized A. muciniphila appears better tolerated and potentially more effective than the live form. The authors themselves flag inconsistencies, risk of bias, and variable certainty across the included studies.
How it was done
Narrative review using PRISMA screening guidelines, encompassing 43 reports from multiple databases up to December 2025, restricted to human supplementation with A. muciniphila.
Risk of bias
This is a narrative review, not a meta-analysis; no quantitative pooling was performed, precluding precise effect estimates. The abstract explicitly acknowledges limited scope, inter-study inconsistencies, risk of bias, and heterogeneous certainty of results.
What this study does NOT prove
The review does not establish causality or confirmed clinical efficacy of A. muciniphila supplementation for metabolic disorders in humans.
In clinical practice
Current evidence does not support routine clinical use of A. muciniphila supplementation for metabolic disorders. Large-scale, long-duration RCTs are required before therapeutic application.
Limitations
This is a narrative review, not a meta-analysis; no quantitative pooling was performed, precluding precise effect estimates. The abstract explicitly acknowledges limited scope, inter-study inconsistencies, risk of bias, and heterogeneous certainty of results.
Technical appendix
Version history
- 1.0 · 2026-08-18 — Auto-generated under Evidence Standard v1.0
Paid access: structured summary from public metadata; consult the original study at the source.